Venus Remedies receives marketing authorisation for Sugammadex in the Philippines, marking a major step in its expansion into complex generics and the ASEAN market. Sugammadex is a relaxant-binding ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge ...

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by ...

Nomura has a Buy rating on Cipla after the company's MD reassured that the competitiveness of the Indian generics biz won't ...

Ever bought a pair of ‘abibas’ slides from Pettah? Or some ‘Colvin Klean’ underwear? No harm if you have (reputational harm ...

The Ireland-headquartered Felix Pharmaceuticals, which is eyeing a valuation of around $200-250 million for the controlling ...

A Tebra survey found that 84% of Americans believe generic medications are just as effective as their brand-name counterparts ...

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue ...

The UK osteoporosis fracture healing market is on a steady growth trajectory, with market size expected to reach USD 738.6 million by 2025. Driven by an increasing prevalence of osteoporosis-related ...

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two ...